|Videos|November 20, 2017

Vaccination Plays a Crucial Role in Reducing Inappropriate Antibiotic Use

James S. Lewis, PharmD, FIDSA, discusses the role vaccination plays in reducing unnecessary antibiotic use.

James S. Lewis, PharmD, FIDSA, Co-Director of Antibiotic Stewardship, Oregon Health and Science University, discusses the role vaccination plays in reducing unnecessary antibiotic use.

Interview Transcript (modified slightly for readability):

"Vaccination is massive in preventing inappropriate antibiotic use because if you don’t get sick, you don’t think you need an antibiotic. The flu vaccine—rightly or wrongly—has a very bad rap for how ineffective it is; oh, it’s only 60% effective. Sixty percent effective is still a whole heck of a lot better than zero percent effective. And when folks end up with the flu, far too often, incorrectly, they end up with an antibiotic prescription. Pneumococcal vaccines are another great example of an area where vaccines have the potential to prevent diseases that lead then to subsequent antibiotic use, which then leads to the development of resistance. So, I think vaccination has got to be a core piece of any sort of strategy to try to minimize antibiotic use in the long run because you don’t need antibiotics if you don’t get sick, and that’s what vaccines are really here to do."


Related to this article

Drawing Borders Around a Borderless Specialty
Editor in chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses the proposed OMB rule restricting federal grants for international research collaboration, and how it threatens infectious disease medicine's inherently borderless surveillance networks, publication access, and knowledge-sharing systems.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.